[go: up one dir, main page]

IS4880A - Innlyksa kompexar af arýl - heterósýklískum söltum - Google Patents

Innlyksa kompexar af arýl - heterósýklískum söltum

Info

Publication number
IS4880A
IS4880A IS4880A IS4880A IS4880A IS 4880 A IS4880 A IS 4880A IS 4880 A IS4880 A IS 4880A IS 4880 A IS4880 A IS 4880A IS 4880 A IS4880 A IS 4880A
Authority
IS
Iceland
Prior art keywords
aryl
heterocyclic salts
internal complexes
complexes
internal
Prior art date
Application number
IS4880A
Other languages
English (en)
Other versions
IS2524B (is
Inventor
Charles Johnson Kevin
Kim Yesook
Mysore Shanker Ravi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4880A publication Critical patent/IS4880A/is
Publication of IS2524B publication Critical patent/IS2524B/is

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
  • Machine Translation (AREA)
IS4880A 1996-05-07 1998-10-27 Innlyksuflókar arýl-heterósýklískra salta. IS2524B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07
PCT/IB1997/000321 WO1997041896A2 (en) 1996-05-07 1997-04-01 Inclusion complexes of aryl-heterocyclic salts

Publications (2)

Publication Number Publication Date
IS4880A true IS4880A (is) 1998-10-27
IS2524B IS2524B (is) 2009-07-15

Family

ID=21791976

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4880A IS2524B (is) 1996-05-07 1998-10-27 Innlyksuflókar arýl-heterósýklískra salta.

Country Status (47)

Country Link
US (2) US6232304B1 (is)
EP (1) EP0900088B1 (is)
JP (1) JP3579060B2 (is)
KR (1) KR20000010823A (is)
CN (1) CN1216923A (is)
AP (1) AP796A (is)
AR (2) AR007002A1 (is)
AT (1) ATE257714T1 (is)
AU (1) AU713711B2 (is)
BG (3) BG64475B2 (is)
BR (1) BR9709213A (is)
CA (1) CA2251912C (is)
CO (1) CO4600677A1 (is)
CZ (1) CZ297847B6 (is)
DE (1) DE69727218T2 (is)
DK (1) DK0900088T3 (is)
DZ (1) DZ2220A1 (is)
EA (1) EA001731B1 (is)
EG (1) EG24135A (is)
ES (1) ES2212809T3 (is)
GE (1) GEP20074185B (is)
GT (1) GT199700044A (is)
HN (1) HN1997000039A (is)
HR (1) HRP970237B1 (is)
HU (1) HU222451B1 (is)
ID (1) ID16866A (is)
IL (1) IL126546A (is)
IS (1) IS2524B (is)
MA (1) MA24172A1 (is)
ME (1) ME00880B (is)
MY (1) MY121999A (is)
NO (1) NO324373B1 (is)
NZ (1) NZ332220A (is)
OA (1) OA10907A (is)
PL (1) PL189324B1 (is)
PT (1) PT900088E (is)
RS (1) RS49532B (is)
SA (1) SA97180024B1 (is)
SI (1) SI0900088T1 (is)
SK (1) SK282032B6 (is)
TN (1) TNSN97075A1 (is)
TR (1) TR199802231T2 (is)
TW (1) TW514529B (is)
UA (1) UA57734C2 (is)
UY (1) UY24544A1 (is)
WO (1) WO1997041896A2 (is)
ZA (1) ZA973874B (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
DE69730902T2 (de) * 1996-05-07 2006-02-23 Pfizer Inc. Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
CN100335047C (zh) 2002-08-20 2007-09-05 布里斯托尔-迈尔斯斯奎布公司 阿立哌唑复合制剂和方法
AU2003263413A1 (en) * 2002-09-17 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
RU2292207C2 (ru) * 2002-10-25 2007-01-27 Пфайзер Продактс Инк. Депо-препараты арилгетероциклических активных веществ в виде суспензии
EP1556086A2 (en) * 2002-10-31 2005-07-27 Pfizer Products Inc. Solid and semi-solid polymeric ionic conjugates
WO2004039410A2 (en) * 2002-10-31 2004-05-13 Pfizer Products Inc. Liquid conjugates of solid pharmaceuticals
EP1418492B1 (en) * 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
MXPA06006291A (es) * 2003-12-08 2006-08-23 Univ Arizona Composiciones anti-cancer sinergisticas.
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
EP1827374B1 (en) * 2004-11-16 2014-11-05 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
DK2081921T3 (da) 2006-07-10 2011-01-03 Paion Uk Ltd Korttidsvirkende benzodiazepinsalte og deres polymorfe former
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β-環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
US20250049709A1 (en) * 2021-12-11 2025-02-13 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DE69730902T2 (de) 1996-05-07 2006-02-23 Pfizer Inc. Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
JP3102896B2 (ja) 1996-05-07 2000-10-23 ファイザー インク. 5―(2―(4―(1,2―ベンズイソチアゾール―3―イル)―1―ピペラジニル)エチル)―6―クロロ―1,3―ジヒドロ―2(1h)―インドール―2―オン(=ジプラシドン)のメシレート三水和物、その調製法およびドーパミンd2アンタゴニストとしてのその使用
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
BG64475B1 (bg) 2005-04-30
WO1997041896A3 (en) 1998-01-08
BR9709213A (pt) 1999-08-10
SK282032B6 (sk) 2001-10-08
AU713711B2 (en) 1999-12-09
EP0900088A2 (en) 1999-03-10
UY24544A1 (es) 2000-09-29
HRP970237A2 (en) 1998-12-31
JPH11509866A (ja) 1999-08-31
CO4600677A1 (es) 1998-05-08
TR199802231T2 (xx) 1999-02-22
AP9700977A0 (en) 1997-07-31
CA2251912A1 (en) 1997-11-13
HRP970237B1 (en) 2002-04-30
NO324373B1 (no) 2007-10-01
HUP9902799A3 (en) 2000-12-28
EA199800910A1 (ru) 1999-04-29
DZ2220A1 (fr) 2002-12-03
US20010031756A1 (en) 2001-10-18
NZ332220A (en) 2000-03-27
IL126546A0 (en) 1999-08-17
NO985192L (no) 1998-11-06
DE69727218D1 (de) 2004-02-19
OA10907A (en) 2001-10-26
EA001731B1 (ru) 2001-08-27
ID16866A (id) 1997-11-20
JP3579060B2 (ja) 2004-10-20
CZ297847B6 (cs) 2007-04-11
MY121999A (en) 2006-03-31
DK0900088T3 (da) 2004-04-19
ATE257714T1 (de) 2004-01-15
CN1216923A (zh) 1999-05-19
DE69727218T2 (de) 2004-11-18
GEP20074185B (en) 2007-08-10
EG24135A (en) 2008-08-06
UA57734C2 (uk) 2003-07-15
YU17297A (sh) 1999-12-27
AU1937297A (en) 1997-11-26
GT199700044A (es) 1998-10-02
PT900088E (pt) 2004-04-30
IL126546A (en) 2001-01-28
EP0900088B1 (en) 2004-01-14
HUP9902799A2 (hu) 1999-12-28
PL329928A1 (en) 1999-04-26
WO1997041896A2 (en) 1997-11-13
RS49532B (sr) 2006-12-15
MA24172A1 (fr) 1997-12-31
SI0900088T1 (en) 2004-04-30
CZ346198A3 (cs) 1999-09-15
SK150498A3 (en) 2000-01-18
SA97180024B1 (ar) 2005-12-24
PL189324B1 (pl) 2005-07-29
AR007002A1 (es) 1999-10-13
BG64474B1 (bg) 2005-04-30
TNSN97075A1 (fr) 2005-03-15
HN1997000039A (es) 1997-06-26
US6399777B2 (en) 2002-06-04
US6232304B1 (en) 2001-05-15
AR045528A2 (es) 2005-11-02
NO985192D0 (no) 1998-11-06
CA2251912C (en) 2003-06-03
KR20000010823A (ko) 2000-02-25
ES2212809T3 (es) 2004-08-01
TW514529B (en) 2002-12-21
AP796A (en) 1999-12-24
ZA973874B (en) 1998-11-06
IS2524B (is) 2009-07-15
HU222451B1 (hu) 2003-07-28
ME00880B (me) 2006-12-15
BG102894A (en) 1999-09-30
BG64475B2 (bg) 2005-04-30

Similar Documents

Publication Publication Date Title
IS4880A (is) Innlyksa kompexar af arýl - heterósýklískum söltum
ID19430A (id) Senyawa senyawa heterosiklik
BR9709230A (pt) Composto
BR9509760A (pt) Composto
DE69713026D1 (de) Positioniervorrichtung
DE69713918D1 (de) Episulfid-Verbindung
FI20010774L (fi) Turboahdinyhdistelmä
BR9707051A (pt) Composto
FI962749L (fi) Uusia heterosyklisiä yhdisteitä
DE59914748D1 (de) Kommutator-kleinmotor
FI973440L (fi) Trisubstituoituja fenyylijohdannaisia
BR9711205A (pt) Composto
ID18027A (id) Garam amina
ID27766A (id) Garam-garam paroksetin
FI963672L (fi) Turboahdin
DE69717920D1 (de) Rotationsmaschine
DE59501902D1 (de) Giessmasse
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
DE59706129D1 (de) Tensidhaltige formulierungen
BR9509740A (pt) Compostos 18-nor-vitamina d
SE9400475D0 (sv) Kompoundmotor
KR970056241U (ko) 자석부착 페이저
SE9801003D0 (sv) Kompoundmotor
ID17127A (id) Pembakaran
EE9400014A (et) Kolb-rootor mootor